TVRD — Tvardi Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1346830 ·
Last close
$3.28
Market Cap
$30.77M
52W High
$5.69
52W Low
$1.50
ADV30
4,286,060
Next earnings
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -7,051,000 -6,804,000 25,817,000 19,851,000 11,312,000
Dec 2025 0 -7,587,000 -7,275,000 32,073,000 20,734,000 11,127,000
Sep 2025 0 -5,938,000 -5,527,000 39,021,000 21,418,000 11,155,000
Jun 2025 0 -8,869,000 4,167,000 43,750,000 1,048,000 10,823,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-23,499,000
Investing CF
$-10,084,000
Financing CF
$22,703,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.89
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-110,450,000
Inventory
$900,000
Receivables
$2,238,000
ST Investments
$10,077,000
EBIT TTM
$-24,433,000
Pretax Income TTM
$-13,541,000
Interest Exp TTM
$2,867,000
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -26,748,000 -18,214,000 32,073,000 11,127,000 -23,499,000
Dec 2024 0 -28,107,000 -29,397,000 35,199,000 126,330,000 -18,305,000
Dec 2023 0 -18,665,000 -17,347,000 27,001,000 89,059,000 -21,040,000
Dec 2022 0 -21,193,000 -20,542,000 45,097,000 90,148,000 -17,866,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.73

Peers — same industry

TickerNameMarket CapLastDaily %
KYNB KYNTRA BIO, INC. $30.79M $7.61
QUCY Quantum Cyber N.V. $30.96M $1.36
DARE Dare Bioscience, Inc. $30.26M $2.02
LSTA LISATA THERAPEUTICS, INC. $29.78M $3.27
SER Serina Therapeutics, Inc. $32.09M $2.14

News headlines (Yahoo Finance, 1h cache)

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
2026-07-09 14:52 · Yahoo
Sector Update: Healthcare Stocks Lower Wednesday Afternoon
2026-07-08 17:48 · Yahoo
Top Midday Gainers
2026-07-08 17:26 · Yahoo
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
2026-07-07 11:00 · Yahoo
Tvardi Therapeutics to Participate in Upcoming Investor Events
2026-05-21 12:00 · Yahoo
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
2026-05-08 11:00 · Yahoo
Sector Update: Health Care Stocks Fall Late Afternoon
2026-04-20 19:55 · Yahoo
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
2026-04-02 12:00 · Yahoo
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
2026-03-31 20:01 · Yahoo
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
2026-02-12 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.